Adhering to the core values of "Customer-centered Care," we are committed to providing safe, effective, and affordable cell therapy for all patients with degenerative diseases. We focus not only on cell product innovation but also on improving accessibility and affordability for patients. We place a high priority on communication with customers throughout the development of cell products.
Treating Heart Failure With hPSC-CMs (HEAL-CHF)
In 2021, Help Therapeutics achieved the first clinical approval (MR-32-21-014649) of iPSC-based cell therapy filed by the National Health Commission of China. We cooperate with Nanjing Drum Tower Hospital to treat heart failure using our iPSC-derived cardiomyocytes.
To learn more about our clinical trial, please check ChinicalTrials.gov.